SMC accepts Vyxeos® for appropriate AML treatment within NHS Scotland

Vertex announces EMA marketing authorisation application validation for cystic fibrosis treatment

The Scottish Medicines Consortium (SMC) has accepted the use of Jazz Pharmaceuticals’ Vyxeos® (daunorubicin and cytarabine) 44 mg/100 mg powder for concentrate for solution for infusion within the NHS in Scotland for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

Outcomes for these patients are historically poor, meaning that they are recognised as having high-risk AML.

AML is a rare form of blood cancer that is particularly difficult to treat. People with high-risk AML have a very poor prognosis; less than 6% survive five years after being diagnosed.

In Scotland, there are approximately 45 new cases of t-AML and AML MRC each year, a number that is expected to rise as the population ages. Due to the seriousness of these forms of cancer, only a small minority of patients are expected to be fit enough to receive Vyxeos.

Vyxeos is an advanced liposomal formulation that delivers a synergistic molar ratio of daunorubicin and cytarabine to the bone marrow. It is the first chemotherapy to demonstrate a significant overall survival benefit versus 7+3 chemotherapy in a Phase 3 study of older patients with t-AML or AML-MRC, and the first treatment option specifically for people who have these types of high-risk AML.

Dr Mark Drummond, Consultant Haematologist at the Beatson Cancer Centre, Glasgow, called the SMC’s acceptance of this treatment “an important milestone for patients who have been diagnosed with t-AML or AML-MRC in Scotland”.

“It is the first new chemotherapy in four decades for these types of high-risk AML that has demonstrated an improved overall survival when compared to a standard of care regimen,” he said. “There has been a real need for new, effective treatment options as response rates to current therapies are substantially lower than those for other types of AML.”

Zack Pemberton-Whiteley, Patient Advocacy Director at Leukaemia Care, said: “The SMC’s announcement is a really positive development for t-AML or AML-MRC patients in Scotland, helping families gain more precious time with their loved ones.”

Dr Kelvin Tan, General Manager, UK and Ireland at Jazz Pharmaceuticals, said: “Jazz welcomes the SMC’s decision to make Vyxeos routinely available on the NHS in Scotland to treat t-AML and AML-MRC.”